Sign In
Buy ACOR
$0.661
+0 (+0%)
At Close: Jul 10, 2024
Acorda Therapeutics Announces Delisting from Nasdaq
05:03pm, Monday, 15'th Apr 2024
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Delisting from Nasdaq.
Acorda Therapeutics Announces Nasdaq Delisting Notification
05:30pm, Wednesday, 03'rd Apr 2024
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Nasdaq Delisting Notification.
Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today?
08:57am, Tuesday, 02'nd Apr 2024
Acorda Therapeutics (NASDAQ: ACOR ) stock is falling hard on Tuesday after the biopharmaceutical company signed a stalking horse asset purchase agreement with Merz Therapeutics. This agreement will h
Acorda Therapeutics shares sink nearly 40% after bankruptcy filing
07:31pm, Monday, 01'st Apr 2024
Shares of Acorda Therapeutics ACOR, +1.96% fell late Monday after the company said it had filed for bankruptcy protection.
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
06:35pm, Monday, 01'st Apr 2024
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement.
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
08:01am, Thursday, 11'th Jan 2024
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025.
Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Call Transcript
05:43pm, Monday, 13'th Nov 2023
Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO,
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
04:01pm, Monday, 13'th Nov 2023
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Third Quarter 2023 Financial Results.
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®.
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
04:01pm, Tuesday, 08'th Aug 2023
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2023 Financial Results.
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
08:00am, Wednesday, 02'nd Aug 2023
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The FightersTM”.
Tom Burns Elected to the Acorda Therapeutics Board of Directors
05:08pm, Wednesday, 28'th Jun 2023
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Tom Burns Elected to the Acorda Therapeutics Board of Directors.
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
08:23am, Monday, 26'th Jun 2023
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement.
Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement
08:00am, Monday, 26'th Jun 2023
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement.
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
04:01pm, Friday, 02'nd Jun 2023
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split.
